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Aim To assess whether B-type natriuretic peptide (BNP) 
can serve as a predictor of end-stage chronic heart failure 
(CHF) in patients with severe systolic dysfunction of the 
systemic right ventricle (SRV).
Methods We performed a retrospective analysis in 28 pa-
tients with severe systolic dysfunction of the SRV (ejection 
fraction 23 ± 6%) who were evaluated as heart transplant 
(HTx) candidates between May 2007 and October 2014. 
The primary endpoints of the study (end-stage CHF) were 
progressive CHF, urgent HTx, and ventricular assist device 
(VAD) implantation. Plasma BNP levels were measured us-
ing a chemiluminescent immunoassay.
Results During median follow-up of 29 months (inter-
quartile range, 9-50), 3 patients died of progressive CHF, 5 
patients required an urgent HTx, and 6 patients underwent 
VAD implantation. BNP was a strong predictor of end-stage 
CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence in-
terval, 1.042-1.117, P<0.001). The following variables with 
corresponding areas under the curve (AUC) were identi-
fied as the most significant predictors of end-stage CHF: 
BNP (AUC 1.00), New York Heart Association functional 
class class III or IV (AUC 0.98), decompensated CHF in the 
last year (AUC 0.96), and systolic dysfunction of the subpul-
monal ventricle (AUC 0.96).
Conclusion BNP is a powerful predictor of end-stage CHF 
in individuals with systolic dysfunction of the SRV.
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Transposition of the great arteries (TGA), the aorta and the 
pulmonary artery, is a congenital heart defect with a mor-
phologically right ventricle pumping blood into systemic 
circulation. It occurs either as complete TGA (D-TGA) or con-
genitally corrected TGA (ccTGA). D-TGA is characterized by 
dextroposition of the systemic ventricle, sinistroposition of 
the subpulmonal morphologically left ventricle, and right-
sided rotation of the great arteries. On the other hand, the 
term ccTGA describes sinistroposition of the the systemic 
ventricle, dextroposition of the subpulmonal morphological-
ly left ventricle, and left-sided rotation of the great arteries (1). 
Preserved left-sided position of the pulmonary venous return 
and right-sided localization of the systemic venous return in 
both types of TGA result in almost complete separation of the 
systemic and pulmonary circulation in D-TGA, which must be 
surgically corrected in early childhood, and physiological cor-
rection of the defect in ccTGA (1). Unfortunately, both the op-
erative correction of D-TGA by atrial tunneling (atrial switch, 
the Mustard or Senning procedure) and anatomic situation 
in ccTGA leave the morphologically right ventricle as the sys-
temic ventricle (1-5). As compared with the morphologically 
left ventricle, tricuspid valve, thin walls, different ventricular 
shape, and myocyte architecture, make this type of the sys-
temic ventricle susceptible to dilatation, development of tri-
cuspid regurgitation, and heart failure (1-5).
Tricuspid regurgitation, systolic dysfunction of the SRV, and 
chronic heart failure (CHF) were associated with impaired 
survival both in individuals with D-TGA (2-4) and ccTGA (5). 
Prognostic stratification of these patients remains notorious-
ly difficult, especially in the presence of SRV systolic dysfunc-
tion. Although B-type natriuretic peptide (BNP) provides 
strong diagnostic and prognostic information in left ventric-
ular systolic dysfunction (6,7), its role in CHF due to SRV failure 
remains poorly understood. BNP and/or N-terminal pro BNP 
correlate just modestly with systolic SRV dysfunction (8-11). 
In addition, there are scarce prognostic data in individuals 
with SRV (11). Importantly, improved prognostic stratifica-
tion could facilitate appropriate use of ventricular assist de-
vices (VAD) and/or heart transplant (HTx) in this population 
(12,13). Therefore, we decided to evaluate whether BNP has 
a prognostic role in individuals with SRV who were referred 
to our heart failure clinic for consideration of HTx.
PatIeNts aNd MetHods
study population and data collection
We performed a retrospective analysis in all patients 
with SRV who were referred to the Heart Failure Clin-
ic of our institution (Institute for Clinical and Experimental 
Medicine, Prague, Czech Republic) between May 2007 and 
October 2014. Available demographic, clinical, laboratory, 
electrocardiographic, and echocardiographic data from the 
first visit to our clinic were collected from the institutional 
database. Doses of angiotensin converting enzyme inhibi-
tors, angiotensin receptor blockers, and beta-blockers were 
expressed as a percentage of the maximum recommend-
ed daily dose according to the latest European Society of 
Cardiology guidelines (14). The patients were followed until 
July 30, 2015. Vital status and the necessity of urgent HTx or 
VAD implantation were recorded. The primary endpoint of 
this study included death, urgent HTx, or VAD implantation. 
It was considered an equivalent of end-stage CHF.
The study group consisted of 28 consecutive patients 
with SRV. This group included 21 patients (75%) after atrial 
switch due to D-TGA (14 patients with the Mustard pro-
cedure, 7 patients with the Senning procedure) and 7 pa-
tients (25%) with ccTGA. The following associated lesions 
were corrected during the primary cardiac surgery: ven-
tricular septal defect in 6 patients with atrial switch, ven-
tricular and atrial septal defect in 1 patient with ccTGA, and 
ventricular septal defect and valvular pulmonary artery 
stenosis in another patient with ccTGA. 5 patients had a 
history of reoperation: 3 patients with atrial switch and 1 
patient with ccTGA required tricuspid valve replacement, 
while additional 1 patient after atrial switch underwent 
aortic valve replacement due to severe regurgitation. All 
20 men (71%) and 8 women (29%) with mean age of 34 
years (range 15-65) had at the first evaluation severe systol-
ic SRV dysfunction with mean ejection fraction of 23 ± 6% 
ranging from 14% to 35%. Median BNP plasma level was 
618 ng/L (interquartile range [IQR] 86.5-1363.5) (Table 1). 
This study conformed to the principles of the Declaration 
of Helsinki. It was approved by the ethics committee of the 
Institute for Clinical and Experimental Medicine, Prague, 
Czech Republic.
Laboratory methods
Blood samples for the measurement of BNP plasma levels 
were collected into chilled tubes containing EDTA (1 mg/
mL) and aprotinin (500 kallikrein inactivator U/mL). Test 
tubes were immediately centrifuged. Plasma BNP levels 
were measured using a chemiluminescent immunoassay 
(Abbott Laboratories, Diagnostics Division, Abbott Park, 
IL, USA, Supplier: Abbott, Max-Planck-Ring 2, Wiesbaden, 
Germany). The lower limit of detection was 10 ng/L, intra-
assay coefficient of variation (CV)<3.8%, and inter-assay 
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taBLe 1. Characteristics of the group with the favorable outcome and the group with an unfavorable outcome (death, urgent heart 
transplantation, ventricular assist device implantation)*
Favorable course 
(group a) N = 14
Unfavorable course
(group B) N = 14 P
age (years), mean ± standard deviation  36.4 ± 15.3   31.5 ± 7.9  0.302
sex (male/female), n (%)   8 (57)/6 (43)   12 (86)/2 (14)  0.209
Body mass index (kg/m2), mean ± standard deviation  23.9 ± 4.1   23.4 ± 3.3  0.306
tGa with atrial switch, n (%)  10 (71)   11 (79)  1.0
type of atrial switch: Mustard/senning, n (%)   5 (36)/5 (36)    9 (64)/2 (14)  0.276
Congenitally corrected tGa, n (%)   4 (29)    3 (21)  1.0
associated lesions corrected at the primary operation, n (%)   5 (36)    3 (20)  0.678
Reoperation- tricuspid valve replacement, n (%)   3 (21)    1 (7)  0.596
Reoperation- aortic valve replacement, n (%)   0    1 (7)  1.0
Implantable cardioverter-defibrillator, n (%)   4 (29)    6 (43)  0.695
History of decompensated heart failure in the last 12 mo, n (%)   1 (7)   14 (100) <0.001
NYHa functional class, n (%) <0.001
I   5 (36)    0
II   8 (57)    0
III   1 (7)    8 (57)
IV   0    6 (43)
Heart rate (beats/min), mean ± standard deviation  64 ± 19   83 ± 18  0.006†
systolic blood pressure (mm Hg), mean ± standard deviation 117 ± 9  108 ± 14  0.016‡ 
Rhythm, n (%)  0.092
sinus  12 (86)    9 (64)
atrial fibrillation   2 (14)    1 (7)
paced   0    4 (29)
QRs duration (ms), mean ± standard deviation 121 ± 27  157 ± 32  0.004†
serum sodium (mmol/L) 138.0 ± 2.0  136.2 ± 4.2  0.166
serum creatinine (µmol/L), mean (interquartile range)  77 (66-87)   97 (81-113)  0.005†
Glomerular filtration rate (mL/min), mean ± standard deviation 122 ± 41  101 ± 39  0.186
B-type natriuretic peptide (ng/L), mean (interquartile range)  91 (64-173) 1342 (1071-3301) <0.001
end-diastolic diameter of the sRV (mm), mean ± standard deviation  53 ± 12   59 ± 16  0.346
ejection fraction of the sRV (%), mean ± standard deviation  26.4 ± 5.7   19.2 ± 3.4  0.001†
Regurgitation on the systemic atrioventricular valve, n (%)  0.037‡
mild   4 (29)    0
moderate   3 (21)    2 (14)
severe   4 (29)   11 (79)
replaced   3 (21)    1(7)
systolic dysfunction of the subpulmonal ventricle, n (%) <0.001
none  14 (100)    1 (7)
mild   0    3 (21)
moderate   0    4 (29)
severe   0    6 (43)
treatment with aCei/sartan, n (%)  14 (100)    9 (64)  0.041‡
equivalent dose of aCei/sartan ≥50% of recommended, n (%)   6 (43)    3 (21)  0.420
treatment with a beta-blocker, n (%)   9 (64)   10 (71)  1.00
equivalent dose of the beta-blocker ≥50% of recommended, n (%)   4 (29)    5 (36)  1.00
treatment with digoxin, n (%)   2 (14)    6 (43)  0.209
treatment with furosemide, n (%)   7 (50)   13 (93)  0.033‡
daily dose of furosemide (mg/d), median (interquartile range)   5 (0-75)   50 (40-65)  0.001†
Mineralocorticoid receptor blocker, n (%)   6 (43)   11 (79)  0.120
*aCei – angiotensin converting enzyme inhibitor; sRV – systemic right ventricle; tGa – transposition of great arteries; NYHa – New York Heart as-
sociation.
†P-value was coded as P < 0.01.
‡P-value was coded as P < 0.05.
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CV<5.3%. For serum creatinine assessment, we used an en-
zymatic method (Abbott Architect Creatinine, catalog No. 
8L24-31, Abbott Laboratories Inc.).
echocardiography
Echocardiography was performed by experienced op-
erators in accordance with the current guidelines of the 
American Society of Echocardiography (15,16). Standard-
ized echocardiographic parasternal and apical views were 
performed on Vivid 7 and Vivid E9 (GE HealthCare, Horten, 
Norway) ultrasound system equipped with a 2-dimension-
al (2D) probe. Parasternal and apical 2- and 4- chamber and 
long axis views were acquired with the high frame rate 
and full image optimization (depth, sector size, gain). All 
acquired images were stored and analyzed off-line using 
commercially available software (EchoPac BT 12, GE Health-
Care). The anatomically right ventricular (RV) end-diastolic 
diameter was measured in RV-focused apical 4-chamber 
view at the basal level. RV volumes and systolic function 
were measured using fractional area change (FAC). The an-
atomically left ventricular (LV) end-diastolic diameter was 
measured in the long axis parasternal view. Biplane disk 
summation method was used for LV volumes and ejec-
tion function assessment (LVEF). The following grading of 
LV systolic dysfunction was used: none (LVEF>55%), mild 
(LVEF 46%-55%), moderate (LVEF 36%-45%), and severe 
(LVEF≤35%). Atrioventricular valve regurgitation was as-
sessed semiquantitatively using Doppler methods (color, 
pulse, continuous wave Doppler). Pulmonary artery pres-
sure was calculated based on continuous Doppler mea-
surement across the left atrioventricular valve with the 
addition of estimated right atrial pressure based on the in-
ferior vena cava diameter and collapsibility.
statistical analysis
Categorical data were described using absolute and rela-
tive frequencies, and compared using χ2 analysis or Fisher 
exact test. Continuous variables were assessed for normal-
ity using the Kolmogorov-Smirnov test. Normally distribut-
ed continuous variables are shown as a mean and standard 
deviation. Not-normally distributed continuous variables 
are shown as a median and interquartile range. Continuous 
variables were compared using the t test for unpaired data 
or non-parametric Mann-Whitney test where appropri-
ate. Univariate Cox regression models were used to iden-
tify the predictors of the primary endpoint. Kaplan-Meier 
curves were constructed to illustrate the relationship 
between selected variables and time-dependent 
events. Due to limited sample size and number of events, 
we could not apply multivariate Cox regression analysis. 
Receiver operating characteristic curve (ROC) analysis and 
Youden’s index (sensitivity + specificity – 100) were used to 
assess and compare the performance of selected variables 
to predict the primary endpoint. For all tests a probability 
value of P < 0.050 was considered significant. All analyses 
were performed using the statistical software SPSS, version 
17.0 (SPSS Inc., Chicago, IL, USA).
ResULts
events during the follow-up
During a median follow-up of 29 months (IQR 9-50), 14 pa-
tients experienced the primary endpoint. 3 patients (11%) 
died of end-stage HF after 5, 14, and 15 months. 5 patients 
(18%) required an urgent HTx (after 4-14 months) and 6 
patients (21%) underwent VAD implantation (HeartMateII, 
Thoratec Corporation, Pleasanton, CA, USA) after 0-17 
months as a bridge to transplant. The remaining 14 indi-
viduals were free of the primary endpoint (group A, favor-
able outcome), whereas the above mentioned 14 patients 
were included in the group B (unfavorable outcome).
Predictors of the unfavorable outcome
Unfavorable outcome in group B was predicted by the fol-
lowing signs of advanced CHF: a history of decompensat-
ed HF in the last 12 months, higher New York Heart As-
sociation (NYHA) functional class, higher heart rate, lower 
systolic blood pressure, markedly elevated plasma levels 
of BNP (Figure 1), higher creatinine serum levels, worse 
FIGURe 1. Comparison of plasma levels of B-type natriuretic 
peptide (BNP) in the group a (favorable outcome) and group B 
(unfavorable outcome). data are shown as a boxplot.
347Hegarova et al: Prognostic stratification in congenital heart disease and systemic right ventricle
www.cmj.hr
tolerance of angiotensin converting enzyme inhibitors or 
sartans, and higher daily doses of furosemide. Advanced 
stage of cardiac remodeling in group B correlated with a 
broader QRS complex on ECG, lower ejection fraction of 
the SRV, higher occurrence of severe regurgitation on the 
systemic atrioventricular valve, and the presence of sys-
tolic dysfunction of the subpulmonal ventricle. Similar re-
sults were revealed using univariate Cox regression analy-
sis (Table 2). Efficacy of clinically relevant predictors of the 
unfavorable outcome was compared using the ROC curve 
analysis (Table 3). The best area under the curve (1.00) and 
the Youden’s index (100%) was found for BNP (optimal cut-
point of 618 ng/L), followed by clinical parameters such as 
NYHA class, a history of decompensated CHF, and systolic 
dysfunction of the subpulmonal ventricle. Other variables 
had a suboptimal predictive capacity (Table 3). Figure 2 il-
lustrates significant separation of Kaplan-Meier curves in 
individuals with BNP plasma levels above and below the 
median.
dIsCUssIoN
To the best of our knowledge, this is the largest clinical 
study that evaluated the prognostic value of BNP in indi-
viduals with severe systolic dysfunction of the SRV. First, 
BNP was found to be a powerful predictor of end-stage 
CHF in individuals with systolic dysfunction of the SRV. Sec-
ond, NYHA functional class III or IV and a history of decom-
pensated CHF, well-known predictors of adverse outcome 
in patients with SRV, and any dysfunction of the subpul-
monal ventricle provided additional important prognostic 
information.
Systolic SRV dysfunction limits the long-term progno-
sis both in individuals with atrial correction of D-TGA and 
ccTGA who frequently die of CHF or malignant arrhyth-
mias. Recent studies demonstrated a cumulative surviv-
al after Mustard correction of D-TGA in the range of 80% 
and 68% at 20 and 39 years, respectively (3,17). Another 
taBLe 2. Results of univariate Cox regression analysis. Predictors of death, urgent heart transplantation, or ventricular assist device 
implantation*
Variables χ2 Hazard ratio (95% confidence interval) P
History of decompensated heart failure in the last 12 mo 25.20 162.20 (1.57-1649.70) <0.001
NYHA functional class (per 1 class) 14.89  16.95 (4.030-71.350) <0.001
Heart rate (per 10 beats/min) 12.51   1.783 (1.284-2.476) <0.001
Systolic blood pressure (per 1 mm Hg)  3.92   0.950 (0.903-1.000)  0.048†
QRS duration (per 10 ms) 12.07   1.403 (1.146-1.719)  0.001‡
Serum sodium (per 1 mmol/L)  6.19   0.776 (0.634-0.949)  0.013†
Serum creatinine (per 10 µmol/L) 29.34   1.347 (1.061-1.710) <0.001
Glomerular filtration rate (per 10 mL/min)  2.68   0.871 (0.736-1.030)  0.101
B-type natriuretic peptide (per 100 ng/L) 29.21   1.079 (1.042-1.117) <0.001
Ejection fraction of the SRV (per 1 percent point)  8.58   0.844 (0.748-0.951)  0.003‡
Severe regurgitation on the systemic atrioventricular valve  7.20   4.98 (1.37-18.14)  0.007‡
Any systolic dysfunction of the subpulmonal ventricle 32.74   2.76 (1.67-4.27) <0.001
Treatment with ACEi/sartan 16.57   0.111 (0.031-0.395) <0.001
Treatment with furosemide  5.51   7.862 (1.024-60.34)  0.008‡
Daily dose of furosemide (per 10 mg/d) 32.62   1.258 (1.097-1.441) <0.001
*aCei – angiotensin converting enzyme inhibitor; sRV – systemic right ventricle; NYHa – New York Heart association.
†P-value was coded as P < 0.05.
‡P-value was coded as P < 0.01.
FIGURe 2. Kaplan-Meier curve illustrates survival without the 
necessity of urgent heart transplantation or ventricular assist 
device implantation according to median of B-type natriuretic 
peptide (BNP) plasma levels (median = 618 ng/L).
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study (18) identified CHF in approximately 20% of individu-
als after atrial switch due to D-TGA and in 30% of patients 
with ccTGA. The most important risk factors of CHF were 
NYHA functional class and systolic dysfunction of the SRV. 
Available studies demonstrated just a modest correlation 
of BNP and/or N-terminal proBNP with the functional sta-
tus and systolic function of the SRV (8-11,19). In addition, 
another two reports found a correlation between worsen-
ing of systolic function of the SRV and increasing levels of 
N-terminal proBNP (20,21). However, just two studies were 
prognostic in nature (11,22). The study of Larson et al (11) 
was underpowered, with 21 patients with systolic dysfunc-
tion of the SRV (ejection fraction ≤45%) and 1 death during 
the follow-up. Not surprisingly, this study failed to detect 
prognostic relevance of natriuretic peptides. On the oth-
er hand, in a study of Haberer et al (22), BNP higher than 
85 ng/L predicted 1 death, necessity of HTx in 3 patients, 
and hospitalization due to decompensated CHF in 8 pa-
tients. These patients were classified as NYHA class I and II 
(91%) with missing echocardiographic data. On the con-
trary, more than 50% of patients in our study group were 
in NYHA class III or IV and they had severe systolic dysfunc-
tion of the SRV (ejection fraction ≤35%).
Although most patients with systolic dysfunction of the 
SRV receive conventional pharmacotherapy for CHF, it 
should be noted that in this population beta-blockers, an-
giotensin converting enzyme inhibitors, and angiotensin 
receptor blockers showed mixed results (23-27). Manage-
ment of adult patients with severe systolic dysfunction of 
the SRV is difficult, because even stable patients in NYHA 
functional class II may progress very quickly to end-stage 
CHF and require advanced non-pharmacological meth-
ods. On the other hand, congenital heart disease has 
been identified as an important risk factor for early 
mortality after HTx. However, the long-term survival 
of these individuals is satisfactory due to young age and 
few comorbidities (12,13). Early mortality may be increased 
due to complicated anatomic situation or sequalae after 
previous corrective cardiac surgery or VAD implantation. 
These complications include tissue adhesions, disappear-
ance of the pericardial space, and allosensitization with 
resulting risk of antibody-mediated rejection. In addition, 
patients with congenital heart disease may spend longer 
time on the waiting list due to specific demands on donors 
and availability of experienced surgeons (28-32). Some au-
thors suggest early enlistment of patients with complex 
congenital heart disease for heart transplant to prevent 
VAD implantation and reduce the number of reoperations 
(31). BNP measurement might facilitate risk stratification in 
patients with failing SRV and could improve the timing of 
non-pharmacological treatment.
There are several limitations of this study. First, the limited 
number of patients and retrospective study design that re-
flect the rare occurrence of CHF due to SRV failure may lim-
it general applicability of the study results. A larger study, 
perhaps a multicenter one, might increase the strength of 
our findings. However, relatively high mortality and mor-
bidity of the studied population allowed even prognostic 
assessment. Second, limited number of events precluded 
the use of multivariate models. Already two variables in 
one model would result in the risk of “overfitting” (33). Fi-
nally, the selected cut-off points predicting the study end-
point have to be considered specific for the studied popu-
lation and may vary in different populations.
In conclusion, BNP is a powerful predictor of end-stage 
CHF in individuals with congenital heart disease and sys-
tolic dysfunction of the SRV. NYHA class III or IV, a history 
of decompensated CHF, and any systolic dysfunction of 
the subpulmonal ventricle provided important addition-
taBLe 3. Results of the receiver operating characteristic curve analysis. selected variables are listed according their accuracy to 
predict the combined endpoint (death, urgent heart transplantation, or ventricular assist device implantation)*
Variable aUC optimal cutpoint Youden’s index
B- type natriuretic peptide (ng/L) 1.00 618 100.0
NYHA functional class 0.98 III  92.9
History of decompensated heart failure in the last year 0.96 yes  92.9
Systolic dysfunction of the subpulmonal ventricle 0.96 yes  92.9
Heart rate (beats per min) 0.83  68  47.2
QRS duration (ms) 0.81 139  62.6
Creatinine (µmol/L) 0.80  90  57.1
Severe tricuspid regurgitation 0.74 yes  47.8
Treatment with furosemide 0.69 yes  39.1
*aUC – area under the curve, NYHa – New York Heart association, sRV – systemic right ventricle.
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al prognostic information. These findings might facilitate 
prognostic stratification in patients with CHF due to the 
SRV failure and could improve the timing of heart trans-
plant enlistment or VAD implantation.
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